Innova Therapeutics has completed its purchase of South Carolina-based biotechnology company Enci Therapeutics. The acquisition includes Enci Therapeutics’ main cancer therapeutic program, IVT-8086.
IVT-8086 is a first-in-class, humanized monoclonal antibody (mAb) developed as a cancer therapeutic that targets and antagonizes the Secreted Frizzled-Related Protein 2 (SFRP2) pathway.
SFRP2 is a protein expressed at high levels in many solid and hematological malignancies, and its expression is correlated with patient outcomes, including overall survival, making it an important therapeutic target. As an SFRP2 antagonist, IVT-8086 selectively blocks the non-canonical Wnt/Ca2+ signaling pathway.
Innova Therapeutics is a Mt. Pleasant, South Carolina-based biotechnology company developing a mAb platform targeting a protein that is highly expressed in various solid cancers and shown to correlate with patient outcomes, including overall survival. Innova’s lead humanized mAb is designated as IVT-8086. Innova’s platform technology has broad treatment options across both hematological and solid malignancies. The development of IVT-8086 is initially focused on targeting cancers including pediatric osteosarcoma, sarcomas, breast cancer, multiple myeloma and pancreatic cancer.
The specific terms of the agreement and financial details of the acquisition have not been disclosed.
According to data captured in the LevinPro HC database, this transaction represents the 122nd Biotechnology transaction of 2025. There were 139 Biotechnology transactions announced in 2024, and 161 announced in 2023.
